Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp …
Full BFRI analysis →
Where BFRI ranks in Drug Manufacturers - Specialty & Generic
Biofrontera Inc. ranks #54 of 91
scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 59%.
The widest moat in the group is Zoetis Inc. (ZTS)
at 85/100.
Moat scores for companies ranked near BFRI in Drug Manufacturers - Specialty & Generic
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 25
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 47
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 12
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 47
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 61
· 15% of the moat score
Scale matters only when it converts into economics.
Biofrontera Inc. (BFRI) scores 37 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #54 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 59%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (61/100) and its weakest is Capital Efficiency (12/100).
How does Biofrontera Inc. compare with other Drug Manufacturers - Specialty & Generic companies?
Biofrontera Inc. ranks #54 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are BGM Group Ltd. (BGM) at 37 just above it and Biofrontera Inc. Warrants (BFRIW) at 37 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.
Why is Biofrontera Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Biofrontera Inc.?
The Corporate Default template measures 6 defenses, and BFRI scores: Pricing Power (36), Cost Advantage (25), Customer Stickiness (47), Capital Efficiency (12), Resilience (47), Scale & Market Position (61). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.